class action lawsuit glp 1 Ozempic Lawsuit: July 2026 Blindness and Gastroparesis Claims glp-1 gastric intestinal obstruction class

Pharmaceutical versions of the incretin mimetic have been modified for longer half-lives that resist immediate breakdown to boost satiety and reduce overall calorie intake

Common injection sites include the abdomen (at least two inches away from the navel), the front or side of the thighs, and the back of the upper arms

P.KozubskiW.LianeriM.DorszewskaJ

[1] [2] These medications enhance insulin secretion in response to meals, suppress glucagon release, slow gastric emptying, and reduce appetite through central nervous system pathways

IDegLira was also indirectly compared to alternative strategies of glycemic control intensification in patients with T2DM treated with basal insulin [29]